Tag: MM

Find relevant news articles from other European projects, below:

CARAMBA  EURE-CART  CARAT Network ATECT PROCROP T2EVOLVE

Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:


Immunotherapy Web Featured Images 111

Can BiTE Molecules Make Off-the-Shelf Immuno-Oncology a Reality?

  Feb 18 2021 Tagged mAbs, BiTE, MM, NHL, LBCL

In hematologic malignancies, a new class of molecules is emerging that may ultimately offer clinical benefits comparable to those chimeric antigen receptor T-cell therapies while reducing some of the negatives associated with them.

Visit website
Multiple6

HDP-101, an antibody-targeted amanitin conjugate to advance to phase I/IIa testi...

  Feb 17 2021 Tagged Abs, ADC, MM, anti-BCMA

The U.S. Food and Drug Administration (FDA) has announced that the B-cell maturation antigen (BCMA) antibody–drug conjugate HDP-101 can proceed to phase I/IIa testing.

Visit website
Immunotherapy Web Featured Images 109

Browse this week's featured selection of scientific publications

A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are are a few highlights from this week.

Visit website
Immunotherapy Web Featured Images 100

Browse this week's featured selection of scientific publications

A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are this week's must-read highlights.

Read more
Immunotherapy Web Featured Images 94

Ide-cel in R/R myeloma: patient-reported outcomes and resistance

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the details of a number of studies investigating idecabtagene vicleucel (ide-cel), a BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy, in relapsed/refractory (R/R) multiple myeloma patients.

Visit website
Immunotherapy Web Featured Images 97

DREAMM-2: Effects of belantamab mafodotin on patient reported outcomes in myelom...

  Feb 03 2021 Tagged MM, mAbs, QoL

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, shares patient-reported outcomes from the DREAMM-2 study (NCT03525678) of single-agent belantamab mafodotin (belamaf) in relapsed/refractory multiple myeloma.

Visit website
Immunotherapy Web Featured Images 98

What are the next steps for CAR-T in myeloma?

  Feb 03 2021 Tagged MM, CAR-T

Sham Mailankody, MBBS, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the future of CAR-T and cellular therapy for multiple myeloma patients. With no currently approved CAR-T therapy for myeloma, he hopes a major advancement will be FDA approval of a BCMA-targeted CAR-T therapy in the near future.

Visit website
VJhemonic15

First-in-human trial of an anti-BCMA ADC for R/R myeloma

  Feb 03 2021 Tagged MM, ADC, anti-BCMA

Meletios Dimopoulos, MD, University of Athens School of Medicine, Athens, Greece, discusses the results of a Phase I, first-in-human dose-escalation trial (NCT03489525) of MEDI2228 in patients with relapsed/refractory (R/R) multiple myeloma.

Visit website
Targeted8

Carfilzomib, Dexamethasone, and Daratumumab Myeloma Treatment Alternative

Hang Quach, MBBS(Hons), SpecCertOC, FRACP, FRCPA, MD, talks about the use of carfilzomib, dexamethasone, and daratumumab as a cheaper alternative for treating relapsed or refractory multiple myeloma as seen in the ALLG MM018/ AMN002 study.

Visit website
vjhemonic19

Myeloma at ASH 2020: talquetemab, CARTITUDE-1 & highlights

  Jan 20 2021 Tagged MM, mAbs, CAR-T

The field of multiple myeloma is rapidly evolving and can be credited to an increased understanding of the biology of the disease leading to an improvement in patients outcomes.

Visit website